Revenue Breakdown
Composition ()
No data
Revenue Streams
Becton Dickinson and Co (BDX) generates its revenue through a diversified portfolio of business segments. Currently, the largest contributor to its top-line growth is Medication Delivery Solutions, accounting for 20.5% of total sales, equivalent to $1.13B. Other significant revenue streams include Medication Management Solutions and Pharmaceutical Systems. Understanding this composition is critical for investors evaluating how BDX navigates market cycles within the Medical Equipment, Supplies & Distribution industry.
Profitability & Margins
Evaluating the bottom line, Becton Dickinson and Co maintains a gross margin of 45.91%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at 13.35%, while the net margin is 7.27%. These profitability ratios, combined with a Return on Equity (ROE) of 6.96%, provide a clear picture of how effectively BDX converts its operational activities into shareholder value.
Comparative Benchmarking
In the context of the broader market, BDX competes directly with industry leaders such as EW and IDXX. With a market capitalization of $50.20B, it holds a significant position in the sector. When comparing efficiency, BDX's gross margin of 45.91% stands against EW's 78.15% and IDXX's 60.35%. Such benchmarking helps identify whether Becton Dickinson and Co is trading at a premium or discount relative to its financial performance.
